Patient  	Patient  	 NN	O
and  	and  	 CC	O
treatment  	treatment  	 NN	B-NP
perspectives 	perspectives 	 NNS	I-NP
:  	:  	 :	O
Revisiting  	Revisiting  	 NNP	O
the  	the  	 DT	O
link  	link  	 NN	O
between  	between  	 IN	O
type  	type  	 NN	O
2  	2  	 CD	O
diabetes 	diabetes 	 NN	O
,  	,  	 ,	O
weight  	weight  	 NN	B-NP
gain 	gain 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
cardiovascular  	cardiovascular  	 JJ	B-NP
risk  	risk  	 NN	I-NP
Lifestyle  	Lifestyle  	 NNP	I-NP
modifications  	modifications  	 NNS	I-NP
in  	in  	 IN	O
conjunction  	conjunction  	 NN	O
with  	with  	 IN	O
antidiabetes  	antidiabetes  	 JJ	B-NP
medications  	medications  	 NN	I-NP
can  	can  	 MD	O
produce  	produce  	 VB	O
near-normal  	near-normal  	 JJ	B-NP
blood  	blood  	 NN	I-NP
glucose  	glucose  	 NN	I-NP
concentrations  	concentrations  	 NNS	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
type  	type  	 NN	B-NP
2  	2  	 CD	I-NP
diabetes  	diabetes  	 NN	I-NP
mellitus  	mellitus  	 NNS	I-NP
( 	( 	 -LRB-	O
T2DM 	T2DM 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Because  	Because  	 IN	O
these  	these  	 DT	O
patients  	patients  	 NNS	O
have  	have  	 VBP	O
increased  	increased  	 VBN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
morbidity  	morbidity  	 NN	I-NP
and  	and  	 CC	O
mortality 	mortality 	 NN	O
,  	,  	 ,	O
treatment  	treatment  	 NN	B-NP
strategies  	strategies  	 NNS	I-NP
should  	should  	 MD	O
also  	also  	 RB	O
address  	address  	 VB	O
the  	the  	 DT	O
cardiovascular  	cardiovascular  	 JJ	B-NP
aspects  	aspects  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
disease 	disease 	 NN	O
,  	,  	 ,	O
including  	including  	 VBG	B-NP
blood  	blood  	 NN	I-NP
pressure 	pressure 	 NN	I-NP
,  	,  	 ,	O
lipids 	lipids 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
body  	body  	 NN	O
weight 	weight 	 NN	O
.  	.  	 .	O
Since  	Since  	 IN	O
the  	the  	 DT	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
abnormalities  	abnormalities  	 NN	O
is  	is  	 VBZ	O
increasingly  	increasingly  	 RB	O
secondary  	secondary  	 JJ	O
to  	to  	 TO	O
poor  	poor  	 JJ	O
diet  	diet  	 NN	O
and  	and  	 CC	O
sedentary  	sedentary  	 JJ	B-NP
lifestyles  	lifestyles  	 NN	I-NP
and  	and  	 CC	O
because  	because  	 IN	O
most  	most  	 JJS	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
T2DM  	T2DM  	 NNP	O
are  	are  	 VBP	O
overweight 	overweight 	 JJ	O
/ 	/ 	 CD	O
obese 	obese 	 NN	O
,  	,  	 ,	O
clinicians  	clinicians  	 NNS	B-NP
are  	are  	 VBP	O
encouraged  	encouraged  	 VBN	O
to  	to  	 TO	O
help  	help  	 VB	O
patients  	patients  	 NNS	O
reduce  	reduce  	 VB	O
body  	body  	 NN	O
weight  	weight  	 NN	O
while  	while  	 IN	O
correcting  	correcting  	 JJ	O
hyperglycemia  	hyperglycemia  	 NN	B-NP
by  	by  	 IN	O
selecting  	selecting  	 VBG	B-NP
treatment  	treatment  	 NN	I-NP
options  	options  	 NNS	I-NP
that  	that  	 WDT	O
improve  	improve  	 VBP	O
both  	both  	 DT	O
parameters 	parameters 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
glucose-lowering  	glucose-lowering  	 JJ	O
properties  	properties  	 NNS	O
of  	of  	 IN	O
insulin  	insulin  	 NN	O
and  	and  	 CC	O
sulfonylureas  	sulfonylureas  	 NNS	B-NP
are  	are  	 VBP	O
well  	well  	 RB	O
known  	known  	 VBN	O
but  	but  	 CC	O
they  	they  	 PRP	O
are  	are  	 VBP	O
also  	also  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
weight  	weight  	 NN	B-NP
gain 	gain 	 NN	I-NP
.  	.  	 .	O
Thiazolidinediones  	Thiazolidinediones  	 NNS	B-NP
are  	are  	 VBP	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
weight  	weight  	 NN	B-NP
gain  	gain  	 NN	I-NP
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
edema 	edema 	 NN	B-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
this  	this  	 DT	O
weight  	weight  	 NN	B-NP
gain  	gain  	 NN	I-NP
may  	may  	 MD	O
be  	be  	 VB	O
more  	more  	 RBR	O
peripheral  	peripheral  	 JJ	O
than  	than  	 IN	O
central 	central 	 JJ	O
,  	,  	 ,	O
which  	which  	 WDT	O
may  	may  	 MD	O
mitigate  	mitigate  	 VB	O
the  	the  	 DT	O
risks  	risks  	 NNS	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
increased  	increased  	 JJ	O
body  	body  	 NN	O
fat 	fat 	 NN	O
.  	.  	 .	O
Metformin 	Metformin 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
consensus  	consensus  	 NN	B-NP
first-line  	first-line  	 JJ	I-NP
drug  	drug  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
T2DM 	T2DM 	 NNP	O
,  	,  	 ,	O
is  	is  	 VBZ	O
weight  	weight  	 NN	B-NP
neutral 	neutral 	 NN	I-NP
.  	.  	 .	O
Newer  	Newer  	 JJR	B-NP
antidiabetes  	antidiabetes  	 JJ	I-NP
agents  	agents  	 NNS	I-NP
include  	include  	 VBP	O
incretin-based  	incretin-based  	 JJ	B-NP
medications 	medications 	 NN	I-NP
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
the  	the  	 DT	O
glucagon-like  	glucagon-like  	 JJ	B-NP
peptide-1  	peptide-1  	 CD	I-NP
receptor  	receptor  	 NN	I-NP
agonists 	agonists 	 NN	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
tend  	tend  	 VBP	O
to  	to  	 TO	O
decrease  	decrease  	 VB	O
weight 	weight 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
dipeptidyl  	dipeptidyl  	 JJ	B-NP
peptidase-4  	peptidase-4  	 CD	I-NP
inhibitors 	inhibitors 	 NN	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
are  	are  	 VBP	O
weight  	weight  	 NN	B-NP
neutral 	neutral 	 NN	I-NP
.  	.  	 .	O
